Figures & data
Figure 1. Glycosylation remodeling of rituximab to prepare rituximab with homogenous N-glycan with 2,6 linked sialic acid using EndoS or EndoS2.
Table 1. Summary of rituximab N-glycan.
Figure 2. HPLC-FLD profile of procainamide labeled N-glycans from rituximab and the glycoengineered rituximab with α2,6 linked sialic acid. A). HPLC profile of rituximab N-glycans with major species shown. B). The glycan profile from the glycoengineered rituximab prepared by Endo S digestion. The major glycan is G2FS2 with α2,6 linked sialic acid. C). The glycan profile from the glycoengineered rituximab after α2-3 Neuraminidase S treatment. D). The glycan profile from the glycoengineered rituximab after α2-3,6,8,9 Neuraminidase A treatment. E). The glycan profile from the glycoengineered rituximab prepared by Endo S2 digestion.
Figure 3. The detection of pyro-E in rituximab. A). Precursor mass of pyro-glutamic acid of the heavy chain from rituximab. B). CID-MSCitation2 of the precursor mass from . The theoretical and observed monoisotopic mass are indicated in the figure.
